JP6267231B2 - カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール - Google Patents

カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール Download PDF

Info

Publication number
JP6267231B2
JP6267231B2 JP2015549756A JP2015549756A JP6267231B2 JP 6267231 B2 JP6267231 B2 JP 6267231B2 JP 2015549756 A JP2015549756 A JP 2015549756A JP 2015549756 A JP2015549756 A JP 2015549756A JP 6267231 B2 JP6267231 B2 JP 6267231B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heterocyclyl
carbocyclyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015549756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507502A5 (enExample
JP2016507502A (ja
Inventor
アッペンダー・ベラパルチ
チェタン・パドマカル・ダルネ
ダームパル・エス・ドッド
アンソニー・ジェイ・サンポグナロ
マーク・ディ・ウィットマン
セルヴァクマル・クマラヴェル
ディバカル・ムリック
チャンドラセカル・レディ・アール
ペイイン・リウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2016507502A publication Critical patent/JP2016507502A/ja
Publication of JP2016507502A5 publication Critical patent/JP2016507502A5/ja
Application granted granted Critical
Publication of JP6267231B2 publication Critical patent/JP6267231B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015549756A 2012-12-21 2013-12-20 カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール Expired - Fee Related JP6267231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740564P 2012-12-21 2012-12-21
US61/740,564 2012-12-21
PCT/US2013/076795 WO2014100533A1 (en) 2012-12-21 2013-12-20 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS

Publications (3)

Publication Number Publication Date
JP2016507502A JP2016507502A (ja) 2016-03-10
JP2016507502A5 JP2016507502A5 (enExample) 2017-01-12
JP6267231B2 true JP6267231B2 (ja) 2018-01-24

Family

ID=49943572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549756A Expired - Fee Related JP6267231B2 (ja) 2012-12-21 2013-12-20 カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール

Country Status (5)

Country Link
US (1) US9556179B2 (enExample)
EP (1) EP2935271B1 (enExample)
JP (1) JP6267231B2 (enExample)
CN (1) CN105073751B (enExample)
WO (1) WO2014100533A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104837844B (zh) 2012-12-21 2017-08-29 百时美施贵宝公司 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN106661056B (zh) * 2014-06-19 2019-07-05 百时美施贵宝公司 作为酪蛋白激酶1δ/ε抑制剂的咪唑并哒嗪衍生物
WO2016081364A1 (en) 2014-11-21 2016-05-26 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as tgf-beta inhibitors
KR20170122799A (ko) 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-β 억제제
US10722513B2 (en) 2015-03-23 2020-07-28 The University Of Melbourne Treatment of respiratory diseases
US10526325B2 (en) 2015-07-31 2020-01-07 Merck Patent Gmbh Bicyclic heterocyclic derivatives
US11053202B2 (en) 2016-09-21 2021-07-06 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
EP3774795B1 (en) * 2018-03-29 2022-03-16 Masarykova Univerzita 4-(1h- imidazol- 5- yl) -1h-pyrrolo [2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors
CN113301900B (zh) * 2018-09-09 2024-11-29 夸纳特制药股份公司 酪蛋白激酶1抑制剂在治疗血管疾病中的应用
AU2019374731B2 (en) 2018-11-07 2025-08-21 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases
US11795160B2 (en) 2019-02-22 2023-10-24 Insilico Medicine Ip Limited Kinase inhibitors
JP2024508818A (ja) 2021-02-24 2024-02-28 インシリコ メディシン アイピー リミテッド 疾患の処置のための類似体
WO2025231112A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof
WO2025231117A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
WO2009137081A2 (en) 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
FR2940284B1 (fr) 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2940285A1 (fr) 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
JP5784620B2 (ja) 2009-10-28 2015-09-24 ファイザー・インク カゼインキナーゼ阻害剤としてのイミダゾール誘導体
CN104837844B (zh) 2012-12-21 2017-08-29 百时美施贵宝公司 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪

Also Published As

Publication number Publication date
EP2935271B1 (en) 2017-10-25
US20150344481A1 (en) 2015-12-03
EP2935271A1 (en) 2015-10-28
WO2014100533A1 (en) 2014-06-26
CN105073751A (zh) 2015-11-18
JP2016507502A (ja) 2016-03-10
US9556179B2 (en) 2017-01-31
CN105073751B (zh) 2018-11-30

Similar Documents

Publication Publication Date Title
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
JP6494622B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
EP2350081B1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
EA029312B1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
AU2014351413B2 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
BR112020026337A2 (pt) Compostos tricíclicos
JP2023537586A (ja) Ｃｄｋ９阻害剤およびその使用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171221

R150 Certificate of patent or registration of utility model

Ref document number: 6267231

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees